Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from CSL ( (AU:CSL) ) is now available.
CSL Limited announced a change in the director’s interest, specifically involving Dr. Paul McKenzie’s indirect holdings. The change included the acquisition of 8,101 ordinary shares and the disposal of 3,699 ordinary shares, along with the exercise and lapse of performance share units under the company’s Performance Rights Plan. This adjustment reflects the company’s ongoing management of executive compensation and performance incentives, which may impact shareholder value and align leadership interests with company performance.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacture of innovative medicines. The company is known for its range of products including vaccines, blood plasma derivatives, and other biopharmaceuticals, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 1,015,272
Technical Sentiment Signal: Sell
Current Market Cap: A$102.3B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.